Is BioNTech Stock a Good Investment?
BioNTech Investment Advice | BNTX |
- Examine BioNTech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research BioNTech's leadership team and their track record. Good management can help BioNTech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact BioNTech's business and its evolving consumer preferences.
- Compare BioNTech's performance and market position to its competitors. Analyze how BioNTech is positioned in terms of product offerings, innovation, and market share.
- Check if BioNTech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about BioNTech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in BioNTech SE stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if BioNTech SE is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine BioNTech Stock
Researching BioNTech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 62.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNTech SE has Price/Earnings To Growth (PEG) ratio of 0.04. The entity recorded a loss per share of 1.97. The firm last dividend was issued on the 2nd of June 2022.
To determine if BioNTech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioNTech's research are outlined below:
| BioNTech SE had very high historical volatility over the last 90 days | |
| About 62.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BioNTech SE Shares Sold by Baader Bank Aktiengesellschaft - MarketBeat |
BioNTech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioNTech SE. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioNTech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact BioNTech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises BioNTech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-05-12 | 2020-03-31 | -0.27 | -0.24 | 0.03 | 11 | ||
2019-11-14 | 2019-09-30 | -0.16 | -0.13 | 0.03 | 18 | ||
2020-03-31 | 2019-12-31 | -0.17 | -0.26 | -0.09 | 52 | ||
2023-08-07 | 2023-06-30 | -0.96 | -0.79 | 0.17 | 17 | ||
2024-05-06 | 2024-03-31 | -1.17 | -1.41 | -0.24 | 20 | ||
2020-08-11 | 2020-06-30 | -0.06 | -0.38 | -0.32 | 533 | ||
2020-11-10 | 2020-09-30 | -0.37 | -0.88 | -0.51 | 137 | ||
2024-03-20 | 2023-12-31 | 2.42 | 1.9 | -0.52 | 21 |
BioNTech Target Price Consensus
BioNTech target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. BioNTech's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 21 | Strong Buy |
Most BioNTech analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand BioNTech stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of BioNTech SE, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBioNTech Target Price Projection
BioNTech's current and average target prices are 122.38 and 136.62, respectively. The current price of BioNTech is the price at which BioNTech SE is currently trading. On the other hand, BioNTech's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
BioNTech Market Quote on 5th of February 2025
Target Price
Analyst Consensus On BioNTech Target Price
BioNTech Analyst Ratings
BioNTech's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about BioNTech stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of BioNTech's financials, market performance, and future outlook by experienced professionals. BioNTech's historical ratings below, therefore, can serve as a valuable tool for investors.Know BioNTech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioNTech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioNTech SE backward and forwards among themselves. BioNTech's institutional investor refers to the entity that pools money to purchase BioNTech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Balyasny Asset Management Llc | 2024-09-30 | 620.5 K | Fred Alger Management, Llc | 2024-09-30 | 500.8 K | Dekabank Deutsche Girozentrale | 2024-12-31 | 481.4 K | First Trust Advisors L.p. | 2024-09-30 | 451.2 K | Quinn Opportunity Partners Llc | 2024-09-30 | 404.5 K | Voloridge Investment Management, Llc | 2024-09-30 | 400.3 K | Abrdn Plc | 2024-12-31 | 385.7 K | Amundi | 2024-09-30 | 366.7 K | Point72 Asset Management, L.p. | 2024-09-30 | 362 K | Baillie Gifford & Co Limited. | 2024-12-31 | 8.2 M | Fmr Inc | 2024-09-30 | 6.3 M |
BioNTech's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 28.08 B.Market Cap |
|
BioNTech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.04 | 0.06 | |
| Return On Capital Employed | 0.03 | 0.03 | |
| Return On Assets | 0.04 | 0.07 | |
| Return On Equity | 0.05 | 0.05 |
Determining BioNTech's profitability involves analyzing its financial statements and using various financial metrics to determine if BioNTech is a good buy. For example, gross profit margin measures BioNTech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioNTech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioNTech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioNTech SE. Check BioNTech's Beneish M Score to see the likelihood of BioNTech's management manipulating its earnings.
Evaluate BioNTech's management efficiency
BioNTech SE has return on total asset (ROA) of (0.0124) % which means that it has lost $0.0124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.024) %, meaning that it created substantial loss on money invested by shareholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2025, whereas Return On Capital Employed is likely to drop 0.03 in 2025. At this time, BioNTech's Return On Assets are fairly stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 75.73 | 79.52 | |
| Tangible Book Value Per Share | 71.37 | 74.94 | |
| Enterprise Value Over EBITDA | 9.45 | 9.92 | |
| Price Book Value Ratio | 1.02 | 1.07 | |
| Enterprise Value Multiple | 9.45 | 9.92 | |
| Price Fair Value | 1.02 | 1.07 | |
| Enterprise Value | 3 B | 3 B |
Understanding the operational decisions made by BioNTech management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.259 |
Basic technical analysis of BioNTech Stock
As of the 5th of February, BioNTech shows the Risk Adjusted Performance of 0.0671, downside deviation of 2.99, and Mean Deviation of 2.4. BioNTech SE technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioNTech's Outstanding Corporate Bonds
BioNTech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioNTech SE uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioNTech bonds can be classified according to their maturity, which is the date when BioNTech SE has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Understand BioNTech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BioNTech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0671 | |||
| Market Risk Adjusted Performance | 0.5748 | |||
| Mean Deviation | 2.4 | |||
| Semi Deviation | 2.86 | |||
| Downside Deviation | 2.99 | |||
| Coefficient Of Variation | 1402.44 | |||
| Standard Deviation | 3.07 | |||
| Variance | 9.4 | |||
| Information Ratio | 0.0456 | |||
| Jensen Alpha | 0.1832 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.0468 | |||
| Treynor Ratio | 0.5648 | |||
| Maximum Drawdown | 14.16 | |||
| Value At Risk | (4.92) | |||
| Potential Upside | 5.55 | |||
| Downside Variance | 8.93 | |||
| Semi Variance | 8.16 | |||
| Expected Short fall | (2.61) | |||
| Skewness | (0.11) | |||
| Kurtosis | 0.001 |
| Risk Adjusted Performance | 0.0671 | |||
| Market Risk Adjusted Performance | 0.5748 | |||
| Mean Deviation | 2.4 | |||
| Semi Deviation | 2.86 | |||
| Downside Deviation | 2.99 | |||
| Coefficient Of Variation | 1402.44 | |||
| Standard Deviation | 3.07 | |||
| Variance | 9.4 | |||
| Information Ratio | 0.0456 | |||
| Jensen Alpha | 0.1832 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.0468 | |||
| Treynor Ratio | 0.5648 | |||
| Maximum Drawdown | 14.16 | |||
| Value At Risk | (4.92) | |||
| Potential Upside | 5.55 | |||
| Downside Variance | 8.93 | |||
| Semi Variance | 8.16 | |||
| Expected Short fall | (2.61) | |||
| Skewness | (0.11) | |||
| Kurtosis | 0.001 |
Consider BioNTech's intraday indicators
BioNTech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioNTech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 42855.35 | |||
| Daily Balance Of Power | 0.8562 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 121.31 | |||
| Day Typical Price | 121.67 | |||
| Price Action Indicator | 3.69 | |||
| Period Momentum Indicator | 5.24 |
BioNTech Corporate Filings
6K | 3rd of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
BioNTech Stock media impact
Far too much social signal, news, headlines, and media speculation about BioNTech that are available to investors today. That information is available publicly through BioNTech media outlets and privately through word of mouth or via BioNTech internal channels. However, regardless of the origin, that massive amount of BioNTech data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioNTech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioNTech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioNTech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioNTech alpha.
BioNTech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioNTech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioNTech Maximum Pain Price Across March 21st 2025 Option Contracts
BioNTech's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of BioNTech close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of BioNTech's options.
BioNTech Corporate Management
| Katalin Kariko | Senior Therapies | Profile | |
| Jens Holstein | CFO Board | Profile | |
| Sylke Maas | Vice Strategy | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Siegbert Kloos | Datand Digital | Profile | |
| Sierk Poetting | COO MD | Profile |
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.